CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting

New models and characterization data being added every month – CTIBiotech
22/03/2018
AACR Congress : April 14-18, Chicago, USA
Join Servier & Oncodesign at the AACR Congress : April 14-18, Chicago, USA
27/03/2018

CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting

CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting

CTIBiotech contributes to the dynamism of oncology research to help an increasing number of patients.

CTIBiotech advances cancer treatments with state-of-the-art 3D-Bioprinting


Launched in 2018, 3D-OncoCHIP is a regional partnership using modern 3D printing methods to provide cancer research with increasingly advanced tools. By reducing development costs and stimulating the emergence of new treatments, CTIBiotech contributes to the dynamism of oncology research to help an increasing number of patients.
Affecting 3 million people in France, cancer has a major impact in terms of public health (150,000 deaths/year), significant social and personal consequences and an increasing cost to the health system over 16 billion euros.
Research into new treatments is a major challenge and a long and expensive process. To reduce development costs, only promising drug candidates should be carried into advanced phases and clinical research. The development of efficient bio-assays, better mimicking the physiological reality, allows this early selection.

Associating two innovative 3D-printing techniques combined with cellular models developed by CTIBiotech within the IMODI Consortium, 3D-OncoCHIP produces three-dimensional micro-tumors containing not only the cancer cells but also their micro-environment.
With this advance, drug candidates can be tested quickly, at high throughput, on models retaining key properties of the patient tumor and thus allowing highly reproducible studies and providing real understanding in drug sensitivity and cell biology.
This regional consortium combines CTIBiotech with three other partners based in Grenoble, Microlight 3D, a young company, and two academic structures the Materials and Physical Engineering Laboratory and the Jean Kuntzmann Laboratory.
Micro tumors are developed in sequences; the first step is creation of a small scale high resolution three-dimension bio-scaffold using bi-photon proprietary polymerization technology that creates the framework where the tumor and cancer micro-environment interact. The second step functionalizes the bio-scaffold in order to provide cancer cells with molecular signaling to better reproduce the patient tissue and environment.

Finally, cells obtained from tumors and their microenvironment will be deposited on the model by bio-extrusion 3D-printing techniques.
Several end-products are expected from our project including the commercialization of micro-tumor chips used for screening of drug candidates in cancer research and a new generation of 3D laser micro-printer that could be used in the development of cell models for other pathologies.

Several new jobs were created for the implementation of this project and a total of 15 new jobs are expected by the end of the project.

3D-OncoCHIP was labelled by LyonBiopôle and Minalogic in 2016 and received an Inter-Ministerial Funding (23rd FUI) in 2017. It is founded by BPI France, the Auvergne-Rhône-Alpes region, the Metropolis of Lyon and the Metropolis of Grenoble, for a total budget of 2.2 M€.




Get connected!

Follow us on: @IMODI_Cancer & www.linkedin.com/company/imodi-cancer


Share this